The Scripps Research Institute and Aileron Therapeutics Enter Exclusive Worldwide Agreement to Utilize "Click" Chemistry for the Development of Stabilized Peptide and Protein Therapeutics
11/30/2010 9:19:20 AM
LA JOLLA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Scripps Research Institute and Aileron Therapeutics™ today announced that they have entered into an agreement that will add Scripps Research’s “Click” chemistry to Aileron’s proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide™ technology. The agreement provides Aileron exclusive worldwide rights to utilize Click chemistry for therapeutics and non-exclusive worldwide rights for diagnostics with Aileron’s stabilized peptide and protein technology platforms. The novel Click chemistries subject to this agreement were developed by Nobel Laureate K. Barry Sharpless, Ph.D., the W.M. Keck Professor of Chemistry at Scripps Research.